Search Results - "BONNETERRE, Jacques"

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER) by André, Fabrice, Prof, Bachelot, Thomas, MD, Commo, Frederic, MSc, Campone, Mario, Prof, Arnedos, Monica, MD, Dieras, Véronique, MD, Lacroix-Triki, Magali, MD, Lacroix, Ludovic, PharmPhD, Cohen, Pascale, PhD, Gentien, David, MSc, Adélaide, Jose, PhD, Dalenc, Florence, MD, Goncalves, Anthony, MD, Levy, Christelle, MD, Ferrero, Jean-Marc, Prof, Bonneterre, Jacques, Prof, Lefeuvre, Claudia, MD, Jimenez, Marta, MSc, Filleron, Thomas, PhD, Bonnefoi, Hervé, Prof

“…Summary Background Breast cancer is characterised by genomic alterations. We did a multicentre molecular screening study to identify abnormalities in…”
Get full text

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer by Macpherson, Iain R, Spiliopoulou, Pavlina, Rafii, Saeed, Saggese, Matilde, Baird, Richard D, Garcia-Corbacho, Javier, Italiano, Antoine, Bonneterre, Jacques, Campone, Mario, Cresti, Nicola, Posner, John, Takeda, Yousuke, Arimura, Akinori, Spicer, James

“…Epertinib (S-222611) is a potent reversible inhibitor of HER2, EGFR and HER4. This trial evaluated the safety, tolerability, pharmacokinetics and antitumour…”
Get full text

Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial by ROCHE, Henri, FUMOLEAU, Pierre, VIENS, Patrice, MONNIER, Alain, VINDEVOGHEL, Anita, CAMPONE, Mario, GOUDIER, Marie-Josèphe, BONNETERRE, Jacques, FERRERO, Jean-Marc, MARTIN, Anne-Laure, GENEVE, Jean, ASSELAIN, Bernard, SPIELMANN, Marc, CANON, Jean-Luc, DELOZIER, Thierry, SERIN, Daniel, SYMANN, Michel, KERBRAT, Pierre, SOULIE, Patrick, EICHLER, Francoise

“…The PACS 01 trial compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen of three cycles of FEC followed by…”
Get full text

Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer by BURZYKOWSKI, Tomasz, BUYSE, Marc, JASSEM, Jacek, BONTENBAL, Marijke, BONNETERRE, Jacques, STEPHEN CHAN, BASARAN, Gul Atalay, THERASSE, Patrick, PICCART-GEBHART, Martine J, SLEDGE, George, CARMICHAEL, James, LÜCK, Hans-Joachim, MACKEY, John R, NABHOLTZ, Jean-Marc, PARIDAENS, Robert, BIGANZOLI, Laura

“…Overall survival (OS) can be observed only after prolonged follow-up, and any potential effect of first-line therapies on OS may be confounded by the effects…”
Get full text

Should a Multigene Signature be Used in all Luminal Early Breast Cancers by Hajjaji, Nawale, Robin, Yves Marie, Bonneterre, Jacques

“…Multigene signatures refine the risk of recurrence and guide adjuvant chemotherapy decision in luminal breast cancers. The decision to perform the assay is…”
Get full text

Egfl7 Promotes Tumor Escape from Immunity by Repressing Endothelial Cell Activation by DELFORTRIE, Suzanne, PINTE, Sébastien, FAVEEUW, Christelle, SONCIN, Fabrice, MATTOT, Virginie, SAMSON, Chantal, VILLAIN, Gaëlle, CAETANO, Bertrand, LAURIDANT-PHILIPPIN, Géraldine, BARANZELLI, Marie-Christine, BONNETERRE, Jacques, TROTTEIN, François

“…Downregulating the leukocyte adhesion molecules expressed by endothelial cells that line tumor blood vessels can limit the entry of immune effector cells into…”
Get full text

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study by Bertucci, François, Prof, Fekih, Mahmoud, MD, Autret, Aurélie, MSc, Petit, Thierry, Prof, Dalenc, Florence, MD, Levy, Christelle, MD, Romieu, Gilles, MD, Bonneterre, Jacques, Prof, Ferrero, Jean-Marc, Prof, Kerbrat, Pierre, Prof, Soulie, Patrick, MD, Mouret-Reynier, Marie-Ange, MD, Bachelot, Thomas, MD, Lerebours, Florence, MD, Eymard, Jean-Christophe, MD, Deblock, Mathilde, MD, Lortholary, Alain, MD, Hardy-Bessard, Anne-Claire, MD, Barthelemy, Philippe, MD, Bonnefoi, Hervé, Prof, Charafe-Jauffret, Emmanuelle, Prof, Bidard, François-Clément, MD, Viens, Patrice, Prof, Lemonnier, Jérôme, PhD, Pierga, Jean-Yves, Prof

“…Summary Background Addition of bevacizumab to standard chemotherapy in the neoadjuvant setting in patients with HER2-negative metastatic breast cancer improves…”
Get full text

A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy by Le Rhun, Emilie, Delbeuck, Xavier, Lefeuvre-Plesse, Claudia, Kramar, Andrew, Skrobala, Emilie, Pasquier, Florence, Bonneterre, Jacques

“…Cognitive impairment, especially verbal episodic memory and executive function impairments, has been considered to be a possible adverse effect of aromatase…”
Get full text

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers by Cottu, Paul H, Bonneterre, Jacques, Varga, Andrea, Campone, Mario, Leary, Alexandra, Floquet, Anne, Berton-Rigaud, Dominique, Sablin, Marie-Paule, Lesoin, Anne, Rezai, Keyvan, Lokiec, François M, Lhomme, Catherine, Bosq, Jacques, Bexon, Alice S, Gilles, Erard M, Proniuk, Stefan, Dieras, Veronique, Jackson, David M, Zukiwski, Alexander, Italiano, Antoine

“…Onapristone is a type I progesterone receptor (PR) antagonist, which prevents PR- mediated DNA transcription. Onapristone is active in multiple preclinical…”
Get full text

Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer by PICCART-GEBHART, Martine J, BURZYKOWSKI, Tomasz, JASSEM, Jacek, BONTENBAL, Marijke, BONNETERRE, Jacques, CHAN, Stephen, BASARAN, Gul Atalay, THERASSE, Patrick, BUYSE, Marc, SLEDGE, George, CARMICHAEL, James, LÜCK, Hans-Joachim, MACKEY, John R, NABHOLTZ, Jean-Marc, PARIDAENS, Robert, BIGANZOLI, Laura

“…Taxanes (paclitaxel or docetaxel) have been sequenced or combined with anthracyclines (doxorubicin or epirubicin) for the first-line treatment of advanced…”
Get full text

Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs by Penel, Nicolas, Adenis, Antoine, Clisant, Stéphanie, Bonneterre, Jacques

“…Summary Dose-limiting toxicity (DLT) remains the preferred metric in dose-finding phase 1 trials. Nevertheless, this primary endpoint appears unsuitable for…”
Get full text

Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial by BONNETERRE, Jacques, ROCHE, Henri, KERBRAT, Pierre, BREMOND, Alain, FUMOLEAU, Pierre, NAMER, Moïse, GOUDIER, Marie-Josèphe, SCHRAUB, Simon, FARGEOT, Pierre, CHAPELLE-MARCILLAC, Isabelle

“…The French Adjuvant Study Group 05 (FASG-05) showed that fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 100 mg/m2 (FEC 100) was superior to…”
Get full text

Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Trials of Adjuvant Epirubicin for Early Breast Cancer: Correlation With Doses of Epirubicin and Cyclophosphamide by PRAGA, Claudio, BERGH, Jonas, KERBRAT, Pierre, HERY, Michel, NILSSON, Jonas, ONIDA, Francesco, PICCART, Martine, SHEPHERD, Lois, THERASSE, Patrick, WILS, Jacques, ROGERS, David, BLISS, Judith, BONNETERRE, Jacques, CESANA, Bruno, COOMBES, R. Charles, FARGEOT, Pierre, FOLIN, Annika, FUMOLEAU, Pierre, GIULIANI, Rosa

“…We reviewed follow-up of patients treated in 19 randomized trials of adjuvant epirubicin in early breast cancer to determine incidence, risk, and risk factors…”
Get full text

Disease-Free Survival Advantage of Weekly Epirubicin Plus Tamoxifen Versus Tamoxifen Alone As Adjuvant Treatment of Operable, Node-Positive, Elderly Breast Cancer Patients: 6-Year Follow-Up Results of the French Adjuvant Study Group 08 Trial by FARGEOT, Pierre, BONNETERRE, Jacques, GUASTALLA, Jean-Paul, GOUDIER, Marie-Josèphe, CHAPELLE-MARCILLAC, Isabelle, ROCHE, Henri, LORTHOLARY, Alain, CAMPONE, Mario, VAN PRAAGH, Isabelle, MONNIER, Alain, NAMER, Moïse, SCHRAUB, Simon, BARATS, Jean-Claude

“…To assess whether an epirubicin (EPI) -based chemotherapy plus hormonal regimen improves disease-free (DFS) in women older than 65 years, with node-positive,…”
Get full text

Long-Term Cardiac Follow-Up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, As Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group by BONNETERRE, Jacques, ROCHE, Henri, VEYRET, Corinne, DATCHARY, Jean, VAN PRAAGH, Isabelle, CHAPELLE-MARCILLAC, Isabelle, KERBRAT, Pierre, FUMOLEAU, Pierre, GOUDIER, Marie-Josèphe, FARGEOT, Pierre, MONTCUQUET, Philippe, CLAVERE, Pierre, BARATS, Jean-Claude, MONNIER, Alain

“…PURPOSE To evaluate long-term cardiac function in patients without disease who had received six cycles of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), and…”
Get full text

Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months' Remission with Lapatinib plus Capecitabine by Mailliez, Audrey, Servent, Véronique, Bonneterre, Jacques, Le Rhun, Emilie

“…Breast tumors overexpressing Her2 (15% of breast cancers) are particularly at risk for central nervous system parenchymal metastases. Whole-brain irradiation…”
Get full text

Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases by Le Rhun, Emilie, Taillibert, Sophie, Boulanger, Thomas, Zairi, Fahed, Bonneterre, Jacques, Chamberlain, Marc C.

“…Background: Survival of patients with leptomeningeal metastases (LM) and impaired functional status is limited to several months, and rarely does neurological…”
Get full text

Prevention of surgical site infection after breast cancer surgery by targeted prophylaxis antibiotic in patients at high risk of surgical site infection by Nicolas, Penel, Yazdan, Yazdanpanah, Marie-Pierre, Chauvet, Stéphanie, Clisant, Sylvia, Giard, Jean-Charles, Neu, Danièle, Lefebvre, Charles, Fournier, Jacques, Bonneterre

“…Objective We previously showed that previous chemotherapy and immediate breast reconstruction were associated with an increased risk of surgical site infection…”
Get full text

Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy by Vieillard, Marie-Hélène, Maes, Jean-Michel, Penel, Guillaume, Facon, Thierry, Magro, Leonardo, Bonneterre, Jacques, Cortet, Bernard

“…Abstract Introduction We report on our experience with 13 cases of jaw osteonecrosis in patients treated with amino-bisphosphonates. Method Data were collected…”
Get full text

Long-term efficacy and toxicity of the FEC100 regimen by Bonneterre, Jacques M

“…Adjuvant chemotherapy has been shown to be beneficial in patients with breast cancer, and anthracycline-containing regimens are more effective than…”
Get more information